Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.54 |
| ▸ | GSPT1 | P15170 | 3/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881351 | 0.85 | CRBN (0.51) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL21069882 | 0.83 | CRBN (0.73) | CRBNDDB1GSPT1IKZF3 | |
| SCHEMBL21069987 | 0.81 | CRBN (0.66) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL20427455 | 0.79 | DDB1 (0.48) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL31389719 | 0.79 | CRBN (0.57) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL25138190 | 0.79 | CRBN (0.50) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL30496995 | 0.79 | CRBN (0.46) | CRBNDDB1IKZF3 | |
| SCHEMBL25246941 | 0.79 | CRBN (0.46) | CRBNDDB1IKZF3 | |
| SCHEMBL24823262 | 0.77 | CRBN (0.66) | CRBNDDB1GSPT1IKZF3 | |
| SCHEMBL29368466 | 0.77 | CRBN (0.60) | CRBNDDB1GSPT1IKZF3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| CN-116457344-A | Low molecular weight protein degradation agent and application thereof | 凯普托尔治疗学股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4188373-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | Captor Therapeutics S.A. (PL) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022029138-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | CAPTOR THERAPEUTICS S.A. (PL) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | MMP2, PSME2, PSME1 | CRBN 251/4885DDB1 784/4885GSPT1 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.